Servier announced the completion of its tender offer to acquire all outstanding shares of Day One Biopharmaceuticals, Inc. on April 23 2026. The transaction was executed at $21.50 per share, valuing Day One at approximately $2.5 billion, a figure that corrects the $1.1 billion estimate in the original article.
The deal brings Day One’s FDA‑approved pan‑RAF inhibitor OJEMDA (tovorafenib) into Servier’s oncology portfolio. OJEMDA, the first systemic therapy approved for pediatric low‑grade glioma, was granted accelerated approval by the FDA on April 23 2024. In addition, the acquisition adds Day One’s expanding pipeline, including the antibody‑drug conjugate Emi‑Le (emiltatug ledadotin) and the DAY301 program, and the rights to OJEMDA outside the United States, which are licensed to Ipsen.
Servier’s 2030 ambition is to lead in rare cancers, especially pediatric low‑grade glioma. The acquisition strengthens that goal by adding a proven product and a pipeline that complements Servier’s earlier 2021 acquisition of Agios Pharmaceuticals, which brought in Voranigo (vorasidenib) for adult and adolescent low‑grade glioma. Together, the assets create a more comprehensive therapeutic offering across the glioma spectrum.
Day One reported revenue of $158 million in the most recent twelve‑month period, with a gross profit margin of 89% but a negative earnings‑per‑share of $1.04. The company’s shares had delivered a 189% return over the past year, and the $21.50 per‑share offer represented a substantial premium to the market price at the time of the tender offer.
The tender offer expired at 11:59 p.m. Eastern Time on April 22 2026, and approximately 85.34% of Day 1’s outstanding shares were validly tendered. Servier’s completion of the transaction on April 23 2026 closed the deal and transferred ownership of the assets and commercial infrastructure to Servier’s global operations.
"This acquisition represents a significant step forward for Servier as part of our 2030 ambition to strengthen our position in rare cancers, and more specifically in pediatric low‑grade glioma," said Olivier Laureau, President of Servier. "Integrating Day One’s scientific and clinical capabilities will enhance our Group’s ability to support long‑term innovation and translate science into meaningful medicines for children and families affected by rare cancers." Jeremy Bender, Ph.D., CEO of Day One, added, "Servier’s successful track record in rare cancers and its commitment to advancing targeted therapies makes it the ideal home for our portfolio as part of Day One’s mission to bring medicines to patients of all ages with life‑threatening diseases." David K. Lee, Executive Vice President, USA, and CEO of Servier Pharmaceuticals, noted, "Welcoming Day One to Servier marks an important next chapter in how we are expanding our presence in oncology in the U.S. and strengthening our ability to deliver for patients."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.